Sitemap
June 02, 2012 Articles
Filter by Available Specialty
- Addition of bevacizumab to chemotherapy doubled PFS among women with platinum-resistant ovarian cancer
- Adolescent and young adult patients with high-risk ALL have poorer survival than younger patients
- ALK inhibitor induced strong response in three types of pediatric cancers
- Pazopanib offered greater quality of life than sunitinib for patients with renal cancer